Related Experiment Video

Updated: May 25, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
10:10

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a

Amy R Cameron1, Katherine Wallace, Lisa Logie

  • 1Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK.

The Biochemical Journal
|January 18, 2012
PubMed

Insights

Clioquinol (CQ) drug regulates the insulin/IGF-1 signaling pathway by affecting the FOXO1a transcription factor and gluconeogenesis. This suggests potential therapeutic strategies for age-related diseases like Alzheimer's and Type 2 diabetes.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Gerontology

Background:

  • Aging diseases like Alzheimer's (AD) and Type 2 diabetes (T2D) share risk factors, implying common aging mechanisms and therapeutic targets.
  • Insulin/IGF-1 signaling (IIS) pathway plays a crucial role in cellular regulation and is implicated in aging and metabolic diseases.

Purpose of the Study:

  • To investigate the insulin-like signaling properties of clioquinol (CQ), an experimental 8-hydroxyquinoline drug.
  • To explore CQ's effects on the Akt/PKB, FOXO1a, and gluconeogenesis, and its potential as a therapeutic agent for age-related diseases.

Main Methods:

  • Examined CQ's effects on IIS kinase Akt/PKB and transcription factor FOXO1a in HEK-293 cells.
  • Assessed CQ's impact on hepatic gluconeogenic gene expression (PEPCK, G6Pase) in rat liver cells.
  • Investigated the role of Zn2+ ions in CQ's observed effects and compared CQ with other 8-hydroxyquinoline compounds.

Main Results:

  • CQ treatment induced responses similar to IIS, including FOXO1a regulation in HEK-293 cells.
  • CQ repressed key gluconeogenic enzymes PEPCK and G6Pase in rat liver cells, requiring Zn2+ ions.
  • CQ demonstrated FOXO1a regulation without diabetogenicity, unlike other 8-hydroxyquinolines.

Conclusions:

  • Zn2+-dependent regulation of FOXOs and gluconeogenesis by CQ may contribute to its therapeutic potential.
  • CQ's distinct signaling profile suggests it as a promising candidate for further investigation in age-related diseases.
  • This study highlights novel pharmacological strategies targeting shared aging mechanisms for diseases like AD and T2D.

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...